{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EU ORPHAN DRUG|Positive" in comments (approximate match)
Status:
Investigational
Source:
INN:efpegsomatropin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01439971: Phase 1 Interventional Completed Hemophilia A
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02226146: Phase 2 Interventional Completed Pemphigoid, Bullous
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03061812: Phase 3 Interventional Completed Small Cell Lung Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01963598: Phase 2 Interventional Completed Sarcopenia
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04050462: Phase 2 Interventional Active, not recruiting Hepatocellular Carcinoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04535674: Phase 2 Interventional Completed COVID-19 Induced Pneumonia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04587830: Phase 2 Interventional Recruiting Glioblastoma Multiforme (GBM)
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02573467: Phase 3 Interventional Completed Sporadic Inclusion Body Myositis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01098266: Phase 3 Interventional Completed Malignant Pleural Mesothelioma
(2010)
Source URL:
Class:
PROTEIN
